R
Rinat Yerushalmi
Researcher at BC Cancer Agency
Publications - 42
Citations - 4747
Rinat Yerushalmi is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 11, co-authored 21 publications receiving 3610 citations. Previous affiliations of Rinat Yerushalmi include University of British Columbia.
Papers
More filters
Journal ArticleDOI
Metastatic Behavior of Breast Cancer Subtypes
Hagen F. Kennecke,Rinat Yerushalmi,Ryan Woods,Maggie C.U. Cheang,David Voduc,Caroline Speers,Torsten O. Nielsen,Karen A. Gelmon +7 more
TL;DR: Breast cancer subtypes are associated with distinct patterns of metastatic spread with notable differences in survival after relapse, and luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases.
Journal ArticleDOI
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon,Marc Tischkowitz,Helen Mackay,Kenneth D. Swenerton,André Robidoux,Katia Tonkin,Hal W. Hirte,David G. Huntsman,Mark Clemons,Blake Gilks,Rinat Yerushalmi,Euan Macpherson,James Carmichael,Amit M. Oza +13 more
TL;DR: The study suggests that olaparib is a promising treatment for women with ovarian cancer and further assessment of the drug in clinical trials is needed.
Journal ArticleDOI
Ki67 in breast cancer: prognostic and predictive potential
TL;DR: An update on the current knowledge on Ki67 and of the evidence in the published work about the prognostic and predictive role of this marker is provided, and information on the laboratory techniques used to determine Ki67 is provided.
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi,William Jacot,Toshinari Yamashita,Joohyuk Sohn,Maria Vidal,Eriko Tokunaga,Junji Tsurutani,Naoto Ueno,Aleix Prat,Yee Soo Chae,Keun Seok Lee,Naoki Niikura,Yeon Hee Park,Bing Xue,Xiao-juan Wang,Miguel Gil-Gil,Wei Liu,Jean-Yves Pierga,Seock-Ah Im,Halle C. F. Moore,Hope S. Rugo,Rinat Yerushalmi,Flora Zagouri,Andrea Gombos,Sung-Bae Kim,Qiang Liu,Ting Luo,Cristina Saura,Peter Schmid,Tao Sun,Dhiraj Gambhire,Lotus Yung,Yibin Wang,Jasmeet Singh,Patrik Vitazka,Gerold Meinhardt,Nadia Harbeck,David Cameron +37 more
TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
Journal ArticleDOI
Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.
Rinat Yerushalmi,Karen A. Gelmon,Samuel Leung,Dongxia Gao,Maggie C.U. Cheang,Michael Pollak,Gulisa Turashvili,Blakes C. Gilks,Hagen F. Kennecke +8 more
TL;DR: IGF-1R correlates with good prognostic markers among patients with early breast cancer and is differentially expressed with variable prognostic impact among breast cancer subtypes.